These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 19944333

  • 21. Hyperkeratotic eruption, hand-foot skin reaction, facial erythema, and stomatitis secondary to multi-targeted kinase inhibitor sorafenib.
    Sahai S, Swick BL.
    Int J Dermatol; 2010 Oct; 49(10):1203-6. PubMed ID: 20883411
    [Abstract] [Full Text] [Related]

  • 22. Acute myocardial infarction caused by simultaneous occlusion of the right coronary artery and the left anterior descending coronary artery probably due to coronary spasm: a case report.
    Suzuki N, Hiasa Y, Miyazaki S, Tomokane T, Ogura R, Miyajima H, Ohara Y, Yuba K, Takahashi T, Hosokawa S, Kishi K, Ohtani R.
    J Cardiol; 2005 May; 45(5):213-7. PubMed ID: 15929389
    [Abstract] [Full Text] [Related]

  • 23. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
    Yang CH, Lin WC, Chuang CK, Chang YC, Pang ST, Lin YC, Kuo TT, Hsieh JJ, Chang JW.
    Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
    [Abstract] [Full Text] [Related]

  • 24. [A case of acute myocardial infarction following intracoronary thrombi caused by coronary artery spasm].
    Kadowaki K, Sato T, Abe Y, Yanagiya N, Kumagai T.
    Kokyu To Junkan; 1992 Jul; 40(7):705-8. PubMed ID: 1518977
    [Abstract] [Full Text] [Related]

  • 25. Sorafenib: atypical cutaneous side effects.
    Richetta AG, Maiani E, Carboni V, Carlomagno V, Cimillo M, Mattozzi C, Calvieri S.
    Eur J Dermatol; 2007 Jul; 17(6):549-50. PubMed ID: 17951148
    [No Abstract] [Full Text] [Related]

  • 26. Dermatologic symptoms associated with the multikinase inhibitor sorafenib.
    Robert C, Mateus C, Spatz A, Wechsler J, Escudier B.
    J Am Acad Dermatol; 2009 Feb; 60(2):299-305. PubMed ID: 19028406
    [Abstract] [Full Text] [Related]

  • 27. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.
    Hutson TE, Bellmunt J, Porta C, Szczylik C, Staehler M, Nadel A, Anderson S, Bukowski R, Eisen T, Escudier B, Sorafenib TARGET Clinical Trial Group.
    Eur J Cancer; 2010 Sep; 46(13):2432-40. PubMed ID: 20656473
    [Abstract] [Full Text] [Related]

  • 28. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study.
    Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE.
    J Clin Oncol; 2010 Feb 20; 28(6):1054-60. PubMed ID: 20085939
    [Abstract] [Full Text] [Related]

  • 29. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
    Bukowski RM, Stadler WM, McDermott DF, Dutcher JP, Knox JJ, Miller WH, Hainsworth JD, Henderson CA, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Figlin RA.
    Oncology; 2010 Feb 20; 78(5-6):340-7. PubMed ID: 20733337
    [Abstract] [Full Text] [Related]

  • 30. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB.
    J Clin Oncol; 2006 Sep 10; 24(26):4293-300. PubMed ID: 16908937
    [Abstract] [Full Text] [Related]

  • 31. Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib.
    Pantaleo MA, Mandrioli A, Saponara M, Nannini M, Erente G, Lolli C, Biasco G.
    BMC Cancer; 2012 Jun 11; 12():231. PubMed ID: 22687270
    [Abstract] [Full Text] [Related]

  • 32. Sorafenib-associated multivessel coronary artery vasospasm.
    Naib T, Steingart RM, Chen CL.
    Herz; 2011 Jun 11; 36(4):348-51. PubMed ID: 21584715
    [Abstract] [Full Text] [Related]

  • 33. Sorafenib-induced erythema multiforme: three cases.
    Namba M, Tsunemi Y, Kawashima M.
    Eur J Dermatol; 2011 Jun 11; 21(6):1015-6. PubMed ID: 21926043
    [No Abstract] [Full Text] [Related]

  • 34. [Application monitoring of the use of sorafenib in papillary renal cell carcinoma].
    Schrader AJ, Hegele A, Olbert P, Buer J, Jeron A, Hofmann R.
    Urologe A; 2007 Sep 11; 46(9):1291. PubMed ID: 17668165
    [No Abstract] [Full Text] [Related]

  • 35. Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib.
    Beldner M, Jacobson M, Burges GE, Dewaay D, Maize JC, Chaudhary UB.
    Oncologist; 2007 Oct 11; 12(10):1178-82. PubMed ID: 17962611
    [Abstract] [Full Text] [Related]

  • 36. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
    Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM.
    J Clin Oncol; 2009 Jul 10; 27(20):3312-8. PubMed ID: 19451442
    [Abstract] [Full Text] [Related]

  • 37. Annular leukocytoclastic vasculitis associated with sorafenib administration.
    Najarian DJ, Packianathan V, Zeitouni NC.
    J Drugs Dermatol; 2010 Jun 10; 9(6):697-8. PubMed ID: 20645534
    [Abstract] [Full Text] [Related]

  • 38. Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview.
    Hutson TE.
    Expert Rev Anticancer Ther; 2007 Sep 10; 7(9):1193-202. PubMed ID: 17892420
    [Abstract] [Full Text] [Related]

  • 39. Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review.
    Kamada P, Dudek AZ.
    Cancer Invest; 2010 Jun 10; 28(5):501-4. PubMed ID: 20014944
    [Abstract] [Full Text] [Related]

  • 40. Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma.
    Eng FC, Easson AM, Szentgyorgyi E, Knox JJ.
    Eur J Surg Oncol; 2009 Feb 10; 35(2):219-21. PubMed ID: 17976949
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.